LAUDICELLA, Riccardo
 Distribuzione geografica
Continente #
EU - Europa 1.273
NA - Nord America 1.107
AS - Asia 237
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 2.620
Nazione #
US - Stati Uniti d'America 1.103
IE - Irlanda 424
SE - Svezia 372
IT - Italia 300
CN - Cina 113
SG - Singapore 53
IN - India 50
PL - Polonia 50
DE - Germania 48
FR - Francia 25
FI - Finlandia 16
BE - Belgio 15
GB - Regno Unito 8
VN - Vietnam 8
IR - Iran 5
AT - Austria 4
NL - Olanda 4
TR - Turchia 4
CA - Canada 2
MX - Messico 2
RO - Romania 2
BR - Brasile 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EU - Europa 1
HK - Hong Kong 1
JP - Giappone 1
LT - Lituania 1
MK - Macedonia 1
MU - Mauritius 1
PH - Filippine 1
TW - Taiwan 1
UA - Ucraina 1
Totale 2.620
Città #
Dublin 422
Chandler 413
Nyköping 290
Messina 84
Princeton 74
Ashburn 68
Medford 61
Warsaw 50
Bremen 37
Des Moines 35
Beijing 30
Rome 28
Hyderabad 27
Singapore 27
Jacksonville 19
Dearborn 17
Brussels 15
Helsinki 15
Los Angeles 15
Palermo 14
Boardman 12
Jinan 12
Ann Arbor 10
Milan 10
Pune 10
Genoa 9
Mumbai 9
Cagliari 8
Dong Ket 8
Nanjing 8
Nanchang 7
Seattle 7
Wilmington 7
Hangzhou 6
Redwood City 6
Shenyang 6
Tianjin 6
Santa Domenica 5
Torregrotta 5
Cambridge 4
Florence 4
Fuzhou 4
Istanbul 4
Munich 4
San Mateo 4
Vienna 4
Waverly Hall 4
Zhengzhou 4
Augusta 3
Changsha 3
Fara Gera d'Adda 3
Haikou 3
Qingdao 3
Rometta Marea 3
Taiyuan 3
Taizhou 3
Bari 2
Bologna 2
Catania 2
Chengdu 2
Chicago 2
Edinburgh 2
Fairfield 2
Fiumefreddo Di Sicilia 2
Hebei 2
Iasi 2
Lanzhou 2
Lecce 2
Meppel 2
Monmouth Junction 2
New York 2
Padova 2
Pedara 2
Pleasant Hill 2
Pozzo Di Gotto 2
Pozzuoli 2
Quinto Di Treviso 2
Rambouillet 2
Reggio Calabria 2
Santa Teresa Di Riva 2
Vittoria 2
Amsterdam 1
Ancona 1
Angeles City 1
Ardabil 1
Balestrate 1
Belpasso 1
Berlin 1
Brno 1
Brooklyn 1
Castelnuovo Rangone 1
Castelvetrano 1
Clifton 1
Codigoro 1
Culver City 1
Duncan 1
Fort Worth 1
Guangzhou 1
Hamburg 1
Hanover 1
Totale 2.021
Nome #
Artificial intelligence in molecular imaging: from machine to deep learning 115
PRRT Retreatments: Renal Function Evaluation 87
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 78
Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation 72
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 71
Safety, effectiveness and haematological toxicity of 223Radichloride: a single Centre experience 67
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 65
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience 64
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 62
Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience 62
[68 Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177 Lu]DOTATOC PRRT: The “Theragnomics” Concept 62
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 61
18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis" 60
Renal Function Evaluation in PRRT Retreatments 59
Clinico-laboratory response and haematological toxicity in patients undergoing therapy with 223RA-dichloride 57
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 57
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 56
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 55
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 52
COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings 49
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 49
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 46
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 46
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 45
18F-FACBC in prostate cancer: A systematic review and meta-analysis 45
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 45
PRRT retreatments: renal function evaluation 44
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study 44
Artifcial intelligence applications in SSTR targeted PET/CT images: prediction of response assessment in GEP-NETs undergoing PRRT with [177Lu]DOTATOC 44
Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers 43
The utility of dual time-point FET-PET/CT in recurrence assessment of glioma patients 43
Correction to: 18F-FMISO PET imaging: insights over MRI in patients with glioma (Clinical and Translational Imaging, (2020), 8, 1, (3-10), 10.1007/s40336-019-00353-0) 41
Prognostic insights of molecular imaging in cardiac sarcoidosis 38
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma 38
Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination 38
Sars-cov-2 persistence: data summary up to q2 2020 37
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature 37
Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience 36
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 35
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 35
Artificial intelligence applications in 68Ga-DOTA PETICT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC 34
Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging 33
Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer 33
[18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review 32
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging 31
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas 30
Artificial intelligence in molecular imaging: from machine to deep learning 29
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome 27
Malignant cutaneous melanoma: Updates in PET imaging 26
Radiomics Analysis of Brain [18 F]FDG PET/CT to Predict Alzheimer’s Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis 26
PET/MR in neuro-oncology: is it ready for prime-time? 25
Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 24
null 23
The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence Also in Comparison with MRI 23
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 22
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT 21
Emerging applications of imaging in glioma: focus on PET/MRI and radiomics 20
Response prediction to PRRT in progressing and metastatic GEP-NET undergoing restaging 68Ga-DOTA PETICT: A preliminary multicenter radiomics study 20
Molecular imaging of pancreatic neoplasms 18
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients 16
null 16
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics 16
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 13
Monitoring of cardiac transthyretin amyloid load by [Tc-99m]DPD scintigraphy: is it the end of the semi-quantitative evaluation? 13
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 11
The role of PET radiomic features in prostate cancer: a systematic review 10
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics 9
PET-based artificial intelligence applications in cardiac nuclear medicine 7
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers 5
PET Imaging in Gliomas: Clinical Principles and Synergies with MRI 4
null 3
mCRPC progression of disease after [177Lu]Lu-PSMA-617 detected on [18F]Choline: a case of PCa heterogeneity 2
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study 1
Totale 2.763
Categoria #
all - tutte 14.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.878


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020110 0 0 0 5 7 15 9 8 3 23 11 29
2020/2021259 22 5 60 6 29 13 12 14 43 27 17 11
2021/2022464 6 30 4 22 31 13 27 34 6 54 35 202
2022/20231.397 119 196 70 107 91 141 17 91 487 16 38 24
2023/2024388 42 40 24 43 44 50 13 35 9 32 16 40
2024/2025110 12 59 39 0 0 0 0 0 0 0 0 0
Totale 2.763